세계의 혈관부종 치료제 시장 보고서(2025년)
Angioedema Treatment Global Market Report 2025
상품코드 : 1764240
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,516,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,419,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

혈관부종 치료제 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 14.6%로 성장할 전망이며, 54억 달러로 성장이 예측됩니다. 예측 기간 동안 전망되는 성장은 헬스케어 지출 증가, 알레르기에 대한 의식 고조, 만성 질환 부담 증가, 혈관부종 발생률 및 유병률의 증가, 맞춤형 의료의 중시 고조와 관련되어 있습니다. 이 기간에 예상되는 주요 동향으로는 진단기술 발전, 기계학습 통합, 연구개발 투자 증가, 원격의료 채택, 규제당국의 승인 및 시장 진입 가속 등이 있습니다.

희귀질환의 발생률 증가는 향후 수년간 혈관부종 치료제 시장의 성장을 가속할 것으로 예측됩니다. 희귀질환은 인구의 극히 일부가 이환되는 병태이며, 종종 중대한 건강 과제와 함께 제한된 치료 선택지를 제시합니다. 이러한 증가는 유전자 검사 및 진단 기술의 진보에 의한 것이 크고, 이전에는 발견되지 않았던 병태를 보다 정확하게 동정 및 진단할 수 있게 되어, 그 결과 보고되고 있는 유병률이 높아지고 있습니다. 혈관부종 치료는 심한 종창 에피소드의 예방과 제어에 도움이 되는 표적 치료를 제공함으로써 유전성 혈관부종과 같은 희귀질환 관리에 중요한 역할을 하며, 최종적으로 환자의 전귀를 향상시키고 있습니다. 예를 들어 2024년 11월 미국 식품의약국은 7,000개가 넘는 희귀질환이 미국의 3,000만 명 이상의 사람들에게 영향을 미치고 있다고 보고했습니다. 이처럼 희귀질환의 이환율 증가가 혈관부종 치료제 시장 확대에 기여하고 있습니다.

혈관부종 치료제 시장의 주요 기업은 급성 유전성 혈관부종(HAE) 발작을 경험하는 환자를 보다 편리하고 신속하게 구제하기 위해 피하 주사와 같은 혁신적인 솔루션 개발을 선호합니다. 피하 주사는 피부 아래에 있는 지방 조직에 약제를 투여하여 혈류에 서서히 흡수시키고 있습니다. 예를 들면, 2025년 4월, 오스트레일리아를 거점으로 하는 바이오 테크놀로지 기업 CSL Limited는, 급성 HAE발작을 예방하기 위해서 설계된 신규의 완전 인간 모노클로날 항체인 ANDEMBRY(갈라다시맙)를 발표했습니다. ANDEMBRY는 월 1회 피하 투여가 승인된 첫 충전된 펜으로, 간편한 장기 예방 선택지를 기재하고 있습니다. 이 약제는 혈관부종을 유발하는 경로의 중요한 컴포넌트인 활성화 제XII인자(제XIIa인자)를 저해함으로써 작용합니다. 이 기술 혁신은 환자 중심의 효과적인 질환 관리를 실현함으로써 HAE 치료에 있어 큰 진전을 의미합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Angioedema treatment involves the medical management of swelling beneath the skin or mucous membranes, which is often triggered by allergic reactions, side effects of medications, genetic disorders, or sometimes unknown factors. The goal of treatment is to alleviate symptoms, prevent airway blockage, and reduce the frequency and severity of episodes.

The primary categories of angioedema treatment include allergic angioedema, drug-induced angioedema, idiopathic angioedema, and hereditary angioedema. Allergic angioedema results from allergic reactions to substances such as certain foods, insect stings, or medications. Treatments may be delivered via injection or oral administration and are used by various end users, including hospitals, clinics, and research institutions.

The angioedema treatment market research report is one of a series of new reports from The Business Research Company that provides angioedema treatment market statistics, including angioedema treatment industry global market size, regional shares, competitors with an angioedema treatment market share, detailed angioedema treatment market segments, market trends and opportunities, and any further data you may need to thrive in the angioedema treatment industry. This angioedema treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The angioedema treatment market size has grown rapidly in recent years. It will grow from $2.72 billion in 2024 to $3.13 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth observed during the historic period can be attributed to increased government support, higher diagnosis rates, a surge in autoimmune disorders, expansion of clinical trials, and improvements in healthcare infrastructure.

The angioedema treatment market size is expected to see rapid growth in the next few years. It will grow to $5.40 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The projected growth during the forecast period can be linked to rising healthcare expenditure, greater awareness of allergies, an increasing burden of chronic diseases, a higher incidence and prevalence of angioedema, and a growing emphasis on personalized medicine. Key trends expected in this period include advancements in diagnostic technologies, integration of machine learning, increased investments in research and development, the adoption of telemedicine, and accelerated regulatory approvals and market access.

An increase in the incidence of rare diseases is anticipated to drive the growth of the angioedema treatment market in the coming years. Rare diseases are medical conditions that affect a small percentage of the population and often present limited treatment options along with significant health challenges. This rise is largely due to advancements in genetic testing and diagnostic technologies, which enable more accurate identification and diagnosis of conditions that were previously undetected, resulting in a higher reported prevalence. Angioedema treatments play a vital role in managing rare diseases like hereditary angioedema by offering targeted therapies that help prevent and control severe swelling episodes, ultimately enhancing patient outcomes. For example, in November 2024, the U.S. Food and Drug Administration reported that over 7,000 rare diseases affect more than 30 million people in the United States. Thus, the growing incidence of rare diseases is contributing to the expansion of the angioedema treatment market.

Leading companies in the angioedema treatment market are prioritizing the development of innovative solutions, such as subcutaneous injections, to provide more convenient and rapid relief for patients experiencing acute hereditary angioedema (HAE) attacks. Subcutaneous injections deliver medication into the fatty tissue beneath the skin, allowing for gradual absorption into the bloodstream. For example, in April 2025, CSL Limited, an Australia-based biotechnology firm, introduced ANDEMBRY (garadacimab), a novel fully human monoclonal antibody designed to prevent acute HAE attacks. ANDEMBRY is the first pre-filled pen approved for once-monthly subcutaneous administration, offering a convenient long-term prophylactic option. The medication works by inhibiting activated Factor XII (Factor XIIa), a key component in the pathway that triggers angioedema. This innovation marks a major step forward in HAE treatment by delivering effective, patient-focused disease management.

In December 2023, Ionis Pharmaceuticals Inc., a U.S.-based biotechnology company, entered into a partnership with Otsuka Pharmaceutical Co., Ltd. to commercialize donidalorsen in Europe for the treatment of hereditary angioedema (HAE). The goal of this collaboration is to expedite the regulatory approval process and facilitate the launch of donidalorsen in the European market, leveraging Otsuka's regional expertise and established market presence. Otsuka Pharmaceutical Co., Ltd., a Japan-based pharmaceutical firm, provides treatments for hereditary angioedema and will play a key role in making this innovative therapy accessible to patients across Europe.

Major players in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

North America was the largest region in the angioedema treatment market in 2024. The regions covered in angioedema treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the angioedema treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The angioedema treatment market consists of revenues earned by entities providing services, such as antihistamine administration, diagnostic services, corticosteroid therapy, genetic counseling, and immunology services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Angioedema Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on angioedema treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for angioedema treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The angioedema treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Angioedema Treatment Market Characteristics

3. Angioedema Treatment Market Trends And Strategies

4. Angioedema Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Angioedema Treatment Growth Analysis And Strategic Analysis Framework

6. Angioedema Treatment Market Segmentation

7. Angioedema Treatment Market Regional And Country Analysis

8. Asia-Pacific Angioedema Treatment Market

9. China Angioedema Treatment Market

10. India Angioedema Treatment Market

11. Japan Angioedema Treatment Market

12. Australia Angioedema Treatment Market

13. Indonesia Angioedema Treatment Market

14. South Korea Angioedema Treatment Market

15. Western Europe Angioedema Treatment Market

16. UK Angioedema Treatment Market

17. Germany Angioedema Treatment Market

18. France Angioedema Treatment Market

19. Italy Angioedema Treatment Market

20. Spain Angioedema Treatment Market

21. Eastern Europe Angioedema Treatment Market

22. Russia Angioedema Treatment Market

23. North America Angioedema Treatment Market

24. USA Angioedema Treatment Market

25. Canada Angioedema Treatment Market

26. South America Angioedema Treatment Market

27. Brazil Angioedema Treatment Market

28. Middle East Angioedema Treatment Market

29. Africa Angioedema Treatment Market

30. Angioedema Treatment Market Competitive Landscape And Company Profiles

31. Angioedema Treatment Market Other Major And Innovative Companies

32. Global Angioedema Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Angioedema Treatment Market

34. Recent Developments In The Angioedema Treatment Market

35. Angioedema Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기